Drug Enforcement D-0239-2023

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Status

Terminated

Classification

Class II

Report Date

February 1, 2023

Termination Date

July 31, 2024

Product Information

Product description
THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/HYDROXYCOBAL 25MG/25MG/25MG/25MG/25MG/20MG/ML (3ML VIAL) INJECTABLE THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/METHYLFOLATE/METHYLCOBAL 10MG/2.5MG/25MG/5MG/5MG/10MG/10MG/ML (1ML VIAL) INJECTABLE THIAMINE/RIBOFLAVIN/NIACINAMIDE/DEXPANTHENOL/PYRIDOXINE 50MG/1MG/100MG/3MG/2MG/ML (30ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
Product quantity
N/A
Reason for recall
Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Recall initiation reason
—
Initial firm notification
Telephone
Distribution pattern
Nationwide in the USA

Location & Firm

Recalling firm
Pharmacy Innovations
Address
2936 W 17th St, N/A

United States
Voluntary / Mandated
Voluntary: Firm initiated
Status date
—

Codes & Dates

Recall number
D-0239-2023
Event ID
91332
Recall initiation date
December 22, 2022
Center classification date
January 26, 2023
Code info
t20221116@36 t20221121@42 t20221021@32
More code info
—